Dublin, Oct. 21, 2013 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/nx5lzf/global_and)
has announced the addition of the "Global
and Chinese Monoclonal Antibody Industry Report, 2013" report
to their offering.
In recent years, the monoclonal antibody market around the globe
has witnessed substantial growth, and the CAGR of market scale
during 1997-2011 has reached 44% approximately. It is predicted
that the global monoclonal antibody market scale will reach USD78
billion in 2012. Meanwhile, monoclonal antibody is also a key major
source of blockbuster drugs. In 2011, the sales of six monoclonal
antibody agents as Infliximab (Johnson & Johnson), Etanercept
(Amgen), Bevacizumab (Roche), Rituximab (Roche), Adalimumab
(Abbvie) and Trastuzumab (Roche) reached above USD5 billion around
the globe, approximating 60% of global monoclonal antibody
market.
Due to the features as high technical threshold, large capital
demand and high rate of return, the international pharmaceutical
giants (including Roche, Johnson & Johnson, Abbvie, Amgen,
Novartis, etc.) are still accelerating the research and
industrialization of monoclonal antibody agents through M&A or
cooperation on the basis of existing monoclonal antibody products.
For example, in April 2012, Amgen and AstraZeneca announced that
they would jointly develop and sell the 5 monoclonal antibody
agents of Amgen under research, namely, AMG827, AMG139, AMG181,
AMG557 and AMG157.
Although the monoclonal
antibody has witnessed rapid development, and the market scale is
expected to share 8%-10% of world's total in 2012, the market in
China is still mainly occupied by imported products. As of the end
of 2012, the number of imported monoclonal antibody products
approved by SFDA amounted to 11, while that of domestic-made
products only reached 8; the number of imported monoclonal antibody
agents approved for clinical tests in China amounted to 27, while
the figure of domestic products only hit 20, mainly imitating the
overseas original drugs.
Key Topics Covered:
1. Overview of Monoclonal Antibody Industry
1.1 Definition
1.2 Classification
1.3 Technological Development
2. Development of Global Monoclonal Antibody Industry
2.1 Development Situation
2.2 Market Scale
2.3 Competitive Pattern
2.4 Development Prospect and Forecast
2.4.1 Market Scale Forecast
2.4.2 Competitive Pattern Forecast
2.4.3 R&D Tendency Prediction
3. Monoclonal Antibody Industry in China
3.1 Development Situation
3.2 Market Scale
3.3 Market Segments
3.3.1 Rituximab/Rituxan®
3.3.2 Trastuzumab/Herceptin®
3.3.3 Cetuximab/Erbitux®
3.3.4 Nimotuzumab
3.3.5 Bevacizumab
3.3.6 Recombinant Human TNF Receptor-Ig Fusion Protein for
Injection
3.4 Competitive Pattern
3.5 Development Prospect
4. Key Enterprises of Monoclonal Antibody Agents Overseas
Companies Mentioned
- AbbVie (Abbott)
- Amgen
- Beijing Biotech Pharmaceutical
- Beijing SL Pharmaceutical
- Chengdu Huasun Group
- Johnson & Johnson
- Merck
- NVS
- Roche Pharmaceuticals
- Shanghai Fosun Pharmaceutical (Group)
- Shanghai Lansheng States Kin Pharmaceutical
- Shanghai Medipharm Biotech
- Shanghai Yalian Antibody Pharmaceutical
- Shenzhen Main Luck Pharmaceuticals
- Yunnan Walvax Biotechnology
- Zhejiang Hisun Pharmaceutical
For more information visit http://www.researchandmarkets.com/research/nx5lzf/global_and
Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector:
Pharmaceuticals